We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Isturisa

News List

Isturisa® continues to show promise in Cushing’s disease europeanpharmaceuticalreview
March 25, 2021
New Phase III trial results show 81 percent of Cushing’s disease patients who received Isturisa® (osilodrostat) had sustained normalisation of mean urinary free cortisol levels.
FDA approves Isturisa (osilodrostat) treatment for Cushing’s disease europeanpharmaceuticalreview
March 10, 2020
The FDA has approved Isturisa for Cushing’s disease treatment after it demonstrated significant efficacy in clinical trials.
FDA approves new treatment for adults with Cushing's disease worldpharmanews
March 09, 2020
The U.S. Food and Drug Administration approved Isturisa (osilodrostat) oral tablets for adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease.